Company Overview
About Humane Genomics
Humane Genomics is a synthetic virology biotech company engineering oncolytic viruses — synthetic RNA viruses designed to selectively infect and destroy cancer cells while leaving healthy cells unharmed — using a proprietary platform that programs viral behavior at the genomic level to create next-generation cancer therapies. The company raised $8.12 million in total funding including a February 2025 round led by Union Square Ventures with 14 investor participants, developing RNA-based viral cancer therapies for systemic delivery designed for extended therapeutic activity.
Business Model & Competitive Advantage
Humane Genomics' synthetic virology platform enables precise engineering of viral genomes to control which cell types the virus infects (cancer cell selectivity through tumor-specific entry mechanisms and replication-dependent killing), how long the virus remains active, and what payloads the virus carries (immune-stimulating transgenes that activate anti-tumor immune responses alongside direct viral killing). The synthetic approach, building viruses from scratch rather than modifying natural viruses, enables more precise control over safety and efficacy characteristics than naturally derived oncolytic virus platforms.
Competitive Landscape 2025–2026
In 2025, Humane Genomics competes in the oncolytic virus and cancer immunotherapy market with Genelux (GL-ONC1), Imvax, Replimune (REPL), and the broader cancer immunotherapy pipeline including checkpoint inhibitors and CAR-T for solid tumor oncology. Oncolytic virotherapy has seen renewed interest as the cancer immunotherapy field looks beyond checkpoint inhibitors (PD-1/PD-L1) for approaches that work in immunologically "cold" tumors that don't respond to immune checkpoint blockade. Union Square Ventures' lead investment reflects the growing biotech-focused investment activity at traditionally software-focused growth funds. The 2025 strategy focuses on preclinical validation of the synthetic virology platform, advancing lead programs toward IND-enabling studies, and building the manufacturing process for synthetic RNA virus production at clinical scale.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Humane Genomics is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Not So Random Others
Zeffy
Zeffy is a Montreal-based fundraising platform for nonprofit organizations that charges zero platform fees on donations — asking donors to optionally contribute a tip to cover Zeffy's operating costs
Oda Studio
Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
Cursor
Cursor is an AI-powered code editor built on Visual Studio Code that integrates advanced language models to provide intelligent code completion, generation, debugging, and refactoring capabilities dir
Kindful
Kindful is a donor management and fundraising platform designed for nonprofit organizations to manage relationships, track donations, and execute fundraising campaigns. The company serves small to mid
Compare Humane Genomics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Humane Genomics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Humane Genomics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Humane Genomics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →